CLINICAL TRIALS PROFILE FOR NARATRIPTAN
✉ Email this page to a colleague
All Clinical Trials for Naratriptan
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00282165 ↗ | Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order | Terminated | FPC De Kijvelanden, Poortugaal | Phase 4 | 2006-11-01 | In a double blind randomized clinical trial with cross-over design, treatment using naratriptan will be compared to placebo within a group of 30 convicts with psychiatric disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that addition of naratriptan to the individual treatment regime reduces aggression -and improves general outcome- as compared to addition of placebo and is well tolerated in this group and under these conditions. |
NCT00282165 ↗ | Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order | Terminated | UMC Utrecht | Phase 4 | 2006-11-01 | In a double blind randomized clinical trial with cross-over design, treatment using naratriptan will be compared to placebo within a group of 30 convicts with psychiatric disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that addition of naratriptan to the individual treatment regime reduces aggression -and improves general outcome- as compared to addition of placebo and is well tolerated in this group and under these conditions. |
NCT00487578 ↗ | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction | Terminated | Clinvest | Phase 4 | 2006-10-01 | The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction. |
NCT00487578 ↗ | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction | Terminated | GlaxoSmithKline | Phase 4 | 2006-10-01 | The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction. |
NCT00487578 ↗ | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction | Terminated | Cady, Roger, M.D. | Phase 4 | 2006-10-01 | The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction. |
NCT01059604 ↗ | Sumatriptan and Naratriptan Pregnancy Registry | Completed | GlaxoSmithKline | 2001-12-01 | Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However, the peak prevalence of migraine is in women of childbearing age. This, coupled with the sporadic nature of migraine attacks and high rates of unplanned pregnancies, makes unintentional exposure to anti-migraine medications during pregnancy likely. Prior to an anti-migraine medication being marketed there are few data available on drug safety in pregnancy: data from animal models may not translate directly to humans and pregnant women are routinely excluded from clinical trials. The Sumatriptan Pregnancy Registry was established by GlaxoSmithKline (GSK) in 1996 to monitor the safety of sumatriptan during pregnancy. It was combined with the Naratriptan Pregnancy Registry in 2001 and data collection on the sumatriptan-naproxen combination (Treximet) began in 2008. | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Naratriptan
Condition Name
Clinical Trial Locations for Naratriptan
Trials by Country
Clinical Trial Progress for Naratriptan
Clinical Trial Phase
Clinical Trial Sponsors for Naratriptan
Sponsor Name